COLL Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 13.07%. Collegium Pharmaceutical's return on equity of 19.31% beat Corcept Therapeutics's return on equity of 21.3%.

Collegium Pharmaceutical has a consensus price target of $43.00, signalling upside risk potential of 48.84%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 96.85%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.629, which suggesting that the stock is 37.082% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Corcept Therapeutics quarterly revenues of $157.2M. Collegium Pharmaceutical's net income of $2.4M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.68x while Corcept Therapeutics's PE ratio is 60.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.67x versus 11.89x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of -7.89%. Collegium Pharmaceutical's return on equity of 19.31% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Collegium Pharmaceutical has a consensus price target of $43.00, signalling upside risk potential of 48.84%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 22.4%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.629, which suggesting that the stock is 37.082% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.736, suggesting its less volatile than the S&P 500 by 26.408%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Collegium Pharmaceutical's net income of $2.4M is higher than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.68x while Supernus Pharmaceuticals's PE ratio is 28.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.67x versus 2.66x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Trevi Therapeutics has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of --. Collegium Pharmaceutical's return on equity of 19.31% beat Trevi Therapeutics's return on equity of --.

Collegium Pharmaceutical has a consensus price target of $43.00, signalling upside risk potential of 48.84%. On the other hand Trevi Therapeutics has an analysts' consensus of $19.83 which suggests that it could grow by 200.51%. Given that Trevi Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Trevi Therapeutics is more attractive than Collegium Pharmaceutical.

Collegium Pharmaceutical has a beta of 0.629, which suggesting that the stock is 37.082% less volatile than S&P 500. In comparison Trevi Therapeutics has a beta of 0.616, suggesting its less volatile than the S&P 500 by 38.428%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevi Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Trevi Therapeutics pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are larger than Trevi Therapeutics quarterly revenues of --. Collegium Pharmaceutical's net income of $2.4M is higher than Trevi Therapeutics's net income of -$11.4M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.68x while Trevi Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.67x versus -- for Trevi Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 1.36% compared to Collegium Pharmaceutical's net margin of 28.42%. Collegium Pharmaceutical's return on equity of 19.31% beat Zoetis's return on equity of 51.03%.

Collegium Pharmaceutical has a consensus price target of $43.00, signalling upside risk potential of 48.84%. On the other hand Zoetis has an analysts' consensus of $194.12 which suggests that it could grow by 21.88%. Given that Collegium Pharmaceutical has higher upside potential than Zoetis, analysts believe Collegium Pharmaceutical is more attractive than Zoetis.

Collegium Pharmaceutical has a beta of 0.629, which suggesting that the stock is 37.082% less volatile than S&P 500. In comparison Zoetis has a beta of 0.942, suggesting its less volatile than the S&P 500 by 5.835%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.17% to investors and pays a quarterly dividend of $0.50 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Collegium Pharmaceutical quarterly revenues are $177.8M, which are smaller than Zoetis quarterly revenues of $2.2B. Collegium Pharmaceutical's net income of $2.4M is lower than Zoetis's net income of $631M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 23.68x while Zoetis's PE ratio is 28.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.67x versus 7.76x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.